Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma

FATE THERAPEUTICS INC

FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.
Phase 1 dose-escalating trial will assess FT522 plus CD20-targeted mAb in relapsed/refractory B-cell lymphoma.
Two regimens: with or without conditioning chemotherapy; starting dose 300M cells per dose in three-dose schedule.
Regimen A enrollment to begin first; Regimen B will start after DLT clearance at initial dose level.
Company presented update at 2023 Jefferies Healthcare Conference on June 7, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.